Document is current
Any future updates will be listed below
-
Authors
Freedland, Stephen J. https://orcid.org/0000-0002-8104-6419
Gao, Wei
Lax, Angela
Yang, Hongbo
Ramaswamy, Krishnan https://orcid.org/0000-0003-0890-0268
Russell, David
Hong, Agnes
Ivanova, Jasmina I. https://orcid.org/0000-0002-4028-9676
-
Funding
Funding for this research was provided by:
Pfizer
Astellas Pharma US
- License Information
-
More Information
Article History
Received: 20 May 2024
Revised: 2 September 2024
Accepted: 3 September 2024
First Online: 13 September 2024
Competing interests
: SJF reports consulting for Astellas Pharma Inc., AstraZeneca, Bayer, Eli Lilly, Exact Sciences, Janssen, Merck, Pfizer Inc., Sanofi, and Sumitomo Pharma America Inc. (formerly Myovant Sciences Inc). WG, AL, and HY are employees of Analysis Group. KR, DR, and JII own stocks or stock options in and are employees of Pfizer Inc., a study sponsor. AH is an employee of Pfizer Inc., a study sponsor, and owns stock in Veru, Revance, and Insmed.
: This study was conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value and rigor and followed generally accepted research practices described in Guidelines for Good Pharmacoepidemiology Practices issued by the International Society for Pharmacoepidemiology.
